**Supplementary Table 3. Association between overall survival and CNA burden after adjustment for purity in IMPACT prostate and pan-cancer cohorts.** Purity was determined by FACETS ([35](#_ENREF_35)).

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Model*** | ***Overall Survival*** | | | | | | | | |
| ***Primary tumors**a, c*** | | | | ***Metastatic tumors**b, d*** | | | | |
| **HR** | **95% CI** | | **P** | **HR** | | **95% CI** | | **P** |
| **Prostate Cancer**: Tumor CNA burden, per 5%, adjusted for purity **a, b** | 1.04 | | 0.98, 1.11 | NS (0.2) | 1.00 | 0.96, 1.05 | | NS (0.9) | |
| **Pan- Cancer**: Tumor CNA burden, per 5%, adjusted for purity c,d | 1.02 | | 1.01, 1.03 | 0.002 | 1.01 | 1.00, 1.02 | | NS (0.061) | |

a Prostate primary tumors: patient n=193; event n=28; median follow-up time for survivors 37 (IQR 25,83) months

b Prostate metastatic tumors: patient n=201; event n=77; median follow-up time for survivors 62.5 (IQR 33, 131) months

c, Pan-cancer primary tumors, n=4052

d Pan-cancer metastatic tumors n=3175